Kai Liu

Kai Liu

Auto-generated profile, based on publicly available information

Kai Liu

Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
KLKai Liu
Kai Liu
RNRalf Nilsson
Ralf Nilsson
ELElisa Lázaro-Ibáñez
Elisa Lázaro-Ibáñez
HDHanna Duàn
Hanna Duàn
TMTasso Miliotis
Tasso Miliotis
ASAlan Sabirsh
Alan Sabirsh
In terms of lipid nanoparticle (LNP) engineering, the relationship between particle composition, delivery efficacy, and the composition of the biocoronas that form around LNPs, is poorly understood. To explore this we analyze naturally efficacious biocorona compositions using an unbiased screening workflow. First, LNPs are complexed with plasma samples, from individual lean or obese male rats, and then functionally evaluated in vitro. Then, a fast, automated, and miniaturized method retrieves the LNPs with intact biocoronas, and multiomics analysis of the LNP-corona complexes reveals the particle corona content arising from each individual plasma sample. We find that the most efficacious LNP-corona complexes were enriched with high-density lipoprotein (HDL) and, compared to the commonly used corona-biomarker Apolipoprotein E, corona HDL content was a superior predictor of in-vivo activity. Using technically challenging and clinically relevant lipid nanoparticles, these methods reveal a previously unreported role for HDL as a source of ApoE and, form a framework for improving LNP therapeutic efficacy by controlling corona composition.

22 July 2021 in Nature Catalysis
Verified
Journal Article
Closed access
PDF file
XSXiaoqiang Shang
Xiaoqiang Shang
HCHao Chen
Hao Chen
VCValentina Castagnola
Valentina Castagnola
KLKai Liu
Kai Liu
Luca BoselliLuca Boselli
Luca Boselli
Jie FanJie Fan
Jie Fan

13 December 2022 in ACS Nano
Verified
Journal Article
Open access
NANima Aliakbarinodehi
Nima Aliakbarinodehi
Audrey GalludAudrey Gallud
Audrey Gallud
MMMokhtar Mapar
Mokhtar Mapar
EWEmelie Wesén
Emelie Wesén
SHSahar Heydari
Sahar Heydari
FHFredrik Höök
Fredrik Höök
Lipid nanoparticles (LNPs) have emerged as potent carriers for mRNA delivery, but several challenges remain before this approach can offer broad clinical translation of mRNA therapeutics. To improve their efficacy, a better understanding is required regarding how LNPs are trapped and processed at the anionic endosomal membrane prior to mRNA release. We used surface-sensitive fluorescence microscopy with single LNP resolution to investigate the pH dependency of the binding kinetics of ionizable lipid-containing LNPs to a supported endosomal model membrane. A sharp increase of LNP binding was observed when the pH was lowered from 6 to 5, accompanied by stepwise large-scale LNP disintegration. For LNPs preincubated in serum, protein corona formation shifted the onset of LNP binding and subsequent disintegration to lower pH, an effect that was less pronounced for lipoprotein-depleted serum. The LNP binding to the endosomal membrane mimic was observed to eventually become severely limited by suppression of the driving force for the formation of multivalent bonds during LNP attachment or, more specifically, by charge neutralization of anionic lipids in the model membrane due to their association with cationic lipids from earlier attached LNPs upon their disintegration. Cell uptake experiments demonstrated marginal differences in LNP uptake in untreated and lipoprotein-depleted serum, whereas lipoprotein-depleted serum increased mRNA-controlled protein (eGFP) production substantially. This complies with model membrane data and suggests that protein corona formation on the surface of the LNPs influences the nature of the interaction between LNPs and endosomal membranes.

6 May 2024 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
Hernán González-King GaribottiHernán González-King Garibotti
Hernán González-King Garibotti
PRPatricia Rodrigues
Patricia Rodrigues
TATamsin Albery
Tamsin Albery
BTBenyapa Tangruksa
Benyapa Tangruksa
RGRamya Gurrapu
Ramya Gurrapu
KJKarin Jennbacken
Karin Jennbacken
Small extracellular vesicles (sEV) derived from various cell sources have been demonstrated to enhance cardiac function in preclinical models of myocardial infarction (MI). The aim of this study was to compare different sources of sEV for cardiac repair and determine the most effective one, which nowadays remains limited. We comprehensively assessed the efficacy of sEV obtained from human primary bone marrow mesenchymal stromal cells (BM‐MSC), human immortalized MSC (hTERT‐MSC), human embryonic stem cells (ESC), ESC‐derived cardiac progenitor cells (CPC), human ESC‐derived cardiomyocytes (CM), and human primary ventricular cardiac fibroblasts (VCF), in in vitro models of cardiac repair. ESC‐derived sEV (ESC‐sEV) exhibited the best pro‐angiogenic and anti‐fibrotic effects in vitro. Then, we evaluated the functionality of the sEV with the most promising performances in vitro, in a murine model of MI‐reperfusion injury (IRI) and analysed their RNA and protein compositions. In vivo, ESC‐sEV provided the most favourable outcome after MI by reducing adverse cardiac remodelling through down‐regulating fibrosis and increasing angiogenesis. Furthermore, transcriptomic, and proteomic characterizations of sEV derived from hTERT‐MSC, ESC, and CPC revealed factors in ESC‐sEV that potentially drove the observed functions. In conclusion, ESC‐sEV holds great promise as a cell‐free treatment for promoting cardiac repair following MI.

26 January 2022 in Nanoscale
Verified
Journal Article
Closed access
PDF file
KLKai Liu
Kai Liu
ASAnna Salvati
Anna Salvati
ASAlan Sabirsh
Alan Sabirsh
Nanomedicines can acquire different biomolecular coronas from various biological contexts. This review offers a practical guide to tuning corona content to match physiological requirements as a necessary step for future nanomedicine success.

13 December 2023 in ACS Nano
Verified
Journal Article
Closed access
GEGustav Emilsson
Gustav Emilsson
KLKai Liu
Kai Liu
FHFredrik Höök
Fredrik Höök
LSLena Svensson
Lena Svensson
LRLouise Rosengren
Louise Rosengren
KSKalle Sigfridsson
Kalle Sigfridsson